# Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma

> **NCT07236528** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 30 (estimated)

## Conditions studied

- Mucosal Melanoma

## Interventions

- **DRUG:** Carilizumab and Apatinib

## Key facts

- **NCT ID:** NCT07236528
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-30
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07236528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07236528, "Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07236528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*